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Background: Diabetes mellitus is an independent risk factor of increased morbidity and mortality in patients with
heart failure. Cardiac resynchronization therapy (CRT), a pacemaker-based therapy for dyssynchronous heart failure,
improves cardiac performance and quality of life, but its effect on mortality in patients with diabetes is uncertain.
Methods: We performed a meta-analysis of results from randomized controlled trials (RCTs) of the long-term outcome
of cardiac resynchronization therapy for heart failure in diabetic and non-diabetic patients. Literature search of MEDLINE
via Pubmed for reports of randomized controlled trials of Cardiac resynchronization for chronic symptomatic left-ventricular
dysfunction in patients with and without diabetes mellitus, with death as the outcome. Relevant data were analyzed by use
of a random-effects model. Reports published from 1994 to 2011 that described RCTs of CRT for treating chronic
symptomatic left ventricular dysfunction in patients with and without diabetes, with all-cause mortality as an outcome.
Results: A total of 5 randomized controlled trials met the inclusion criteria, for 2,923 patients. The quality of studies was
good to moderate. Cardiac resynchronization significantly reduced the mortality for heart failure patients with or without
diabetes mellitus. Mortality was 24.3% for diabetic patients with heart failure and 20.4 % for non-diabetics (odds ratio 1.28,
95% confidence interval 1.06–1.55; P = 0.010).
Conclusions: Cardiac resynchronization therapy (CRT) may reduce mortality from progressive heart failure in patients with
or without diabetes mellitus, but mortality may be higher for patients with than without diabetes after CRT for heart
failure.
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The strong association of diabetes mellitus (DM) and
Heart failure (HF) has been well recognized for several de-
cades. These two chronic medical conditions often coexist.
The prevalence of DM in patients with HF approaches
30% [1]. DM contributes to the development and progres-
sion of HF and worsens the prognosis. Patients with both
DM and HF have a 1.5- to 2-fold higher risk of death than
non-diabetic patients with HF [2]. Despite the develop-
ment of effective pharmacological and non- pharmaco-
logical treatments in recent years, the quality of life of* Correspondence: suguohai2@sohu.com
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(http://creativecommons.org/publicdomain/zeromany patients with HF is considerably impaired because
of the frequent worsening of symptoms and continual
poor prognosis, with sudden cardiac death as the major
cause of death [3].
Cardiac resynchronization therapy (CRT) is an exciting
therapy that can treat patients with systolic heart failure
(HF) and left ventricular dysfunction who have a wide
QRS complex. Fortunately, recent studies [4,5] have dem-
onstrated the beneficial effect of cardiac resynchronization
therapy (CRT) to improve symptoms, exercise capacity,
and left ventricular (LV) systolic performance in HF pa-
tients with low ejection fraction and wide QRS complex.
But the pathophysiology underlying HF in diabetic pa-
tients differs from that in nondiabetes. Reports on CRT in
diabetic patients are limited and controversial. Whetherle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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DM is not well established.
We aimed to systemically review the literature to de-
termine the effect of CRT on death in end-stage HF pa-
tients with and without DM.
Methods
Study search
We performed a literature search of MEDLINE via
Pubmed for articles published from 1994 to 2012 de-
scribing RCTs of CRT for HF in patients with or without
DM. RCTs had to include death as an outcome. Studies of
CRT were first reported in 1994 [6]. The search was per-
formed in January 2013. To focus on the chronic effects of
CRT, we excluded reports of trials with <3-month follow-
up. For multiple reports from the same trial, we used the
most complete and/or recently reported data.
Data abstraction
Two reviewers assessed report eligibility and abstracted
data independently in an unblended [7] standardized man-
ner. Abstracted data included eligibility criteria, baseline
characteristics of patients, interventions, outcomes, and re-
ported methodological quality (internal validity). The out-
come of interest was death from any cause. Disagreements
between reviewers were resolved by consensus.
Data analysis
Because of relatively low event rates, odds ratios (ORs)
closely approximated risk, and we collected OR data from
reports. OR were pooled by use of a random-effects model
with weighting based on inverse variance calculated ac-
cording to DerSimonian and Laird [8]. Chi-square test
was used to check for quantitative heterogeneity. WeFigure 1 Selective flowchart of studies included in the meta-analysis.performed sensitivity analyses to determine the effect of
changes in assumptions on the association of CRT and
mortality. Publication bias was assessed with funnel plots.




The selection of reports is described in Figure 1. We
identified 2,548 potentially relevant reports; 2,523 were
excluded after reading the title and abstract. We re-
trieved the full-text versions of the remaining 25 reports,
and only 5 were eligible for inclusion [9-13].
Characteristics of patients
Baseline patient characteristics (Table 1) were similar in
the 5 trials [9-13]: at the time of CRT implantation, all pa-
tients had moderate to severe HF, with New York Heart
Association (NYHA) functional class III or IV HF despite
stable (>3 months) optimized medical therapy, severe left
ventricular systolic dysfunction of any cause (ejection frac-
tion ≤35%, end-diastolic diameter >55 mm) and ventricu-
lar conduction disturbances (QRS duration ≥120 ms).
Mean ages ranged from 63 to 67 years and mean left ven-
tricular ejection fraction from 21% to 28%. Most patients
were men. For more than 54% of patients (2 trials), HF re-
sulted from ischemic cardiomyopathy [9,10,13]. In con-
trast, in each of the 3 other trials, most patients had
non-ischemic cardiomyopathies [11,12] (Figure 2). Base-
line QRS duration, a measure of ventricular electrical
dyssynchrony, was reported similarly prolonged for each
of the 5 trials, with mean values ranging from 158 to
176 ms. Dyssynchrony was associated with left bundle-
branch block for most patients in each trial. Baseline use
Table 1 Characteristics of trials included in the meta-analysis
Kiès et al. 2005 [9] Ghali et al. 2007 [2010] Hoppe et al. 2007 [11] Fantoni et al. 2008 [12] Mangiavacchi et al. 2008 [13]
No. of patients
randomized
97 1211 813 355 447
Age, mean, y 63 66 67 63 ± 9 65.7 ± 9.7
Men, % 77 67 74 75 81
LVEF, mean, % 22 22 25 21.2 ± 6.2 28.9 ± 6.1
NYHA functional
class, range
III-IV III-IV III-IV III-IV II-IV
Ischemic
cardiomyopathy, %
62 55 40 47 54
QRS duration, mean,
ms
176 158 160 163 166
ACEI inhibitor or ARB, % 88 88 95 98 99.3
insulin-treated
diabetic patients, (%)
9 (28.1) - 85 (10.5) 57 (40.4) 29 (31.9)
Follow-up,
randomized, mo
6 12 36.4 35 36
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receptor blocker was similarly high for all 5 trials and
ranged from 88% to 98% (Table 1).
There is statistically significant increase in LVEF and
6-min walking test both in nondiabetic and in diabetic
patients, with a trend toward a greater increase in the
nondiabetic group cardiomyopathy after CRT [9,11-13].
CRT also reduced all-cause mortality in all patients with
HF, regardless of presence of diabetes. For individual tri-
als, mortality did not differ between diabetics and non-
diabetics (Figure 3). However, on pooling data by a
random-effects model, diabetes with HF was associated
with a significant increase in death (OR 1.28; 95% confi-
dence interval [95% CI] 1.06–1.55; P = 0.010). Pooled ab-
solute rates of mortality during follow-up were 24.3% forFigure 2 Prevalence of coronary artery disease in patients with or witHF patients with diabetes and 20.4% for nondiabetics.
Chi-square test of ORs of mortality revealed no hetero-
geneity (P =0.33).
Sensitivity analyses
We performed sensitivity analyses to determine the effect
of changes in assumptions on the association of CRT and
reduced mortality with HF and diabetes (Table 2). First,
we compared fixed-effects and random-effects statistical
models. The 2 types of models had similar results.
Second, we analyzed data for only patients with NYHA
functional class III and IV (moderate to severe HF) be-
cause the US Food and Drug Administration has ap-
proved CRT devices for such patients. The point
estimate of the OR for death from HF for 2,476 class IIIhout diatetes. *P < 0.05, P < 0.01, P < 0.001.
Figure 3 Death among patients with cardiac resynchronization for heart failure for patients with or without diabetes.
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III, and IV patients (1.24 vs. 1.28) (Table 2).
Third, we assessed the influence of individual trials on
the pooled OR for death from HF. By excluding individ-
ual trials, the point estimates for the OR changed little
and ranged from 1.24 to 1.46 (Table 2). Therefore, no
single study had a major impact on the point estimate of
the pooled OR.
Publication bias
The funnel plot for all-cause mortality during follow-up
appeared symmetric, which suggested the absence of
publication bias (Figure 4).
Discussion
This meta-analysis of reports of CRT for HF in patients
with and without diabetes was of a large cohort of pa-





NYHA baseline functional class
II-IV 5
III-IV 4
Analysis with all studies except
Kiès 2005 [9] 4
Hoppe 2007 [11] 4
Ghali 2007 [10] 4
Fantoni 2008 [12] 4
Mangiavacchi 2008 [13] 4
Abbreviations: NYHA, New York Heart Association. Odds ratio, pooled odds ratio of
more than 1.0 favors non-diabetes. 95% CI, 95% confidence interval.significant reduction in all-cause mortality for nondia-
betic than diabetic patients. Thus, diabetic patients with
advanced HF undergoing CRT may have an increased
risk of mortality than nondiabetic patients. This in-
creased risk of death seems to be due mainly to insulin-
treated diabetes; the mortality estimates for nondiabetic
patients and noninsulin-treated diabetic patients were
similar, with the mortality estimate for insulin-treated
patients substantially worse [13].
An important number of patients with HF have con-
comitant DM, for worse prognosis, likely because of the
different underlying etiology of HF in patients with DM,
who show increased hypertension, dyslipidemia and ag-
gressive atherosclerosis. Previous reports suggested that
diabetic patients were sicker than nondiabetic patients and
presented a significantly higher prevalence of permanent
atrial fibrillation and renal function impairment, larger left
ventricles, and higher pulmonary artery systolic pressureization on death in patients with and without diabetes
No. of patients analyzed Death from heart failure










death from all cause among patients with diabete or non-diabetes. Odds ratio
Figure 4 Funnel plot of all studies in the meta-analysis of risk of all-cause mortality for patients with and without diabetes. SE = standard
error; OR = odds ratio.
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tissue and alterations in myofibrillar proteins, which are
frequently observed in diabetic patients. Accumulating de-
position of interstitial fibrotic tissue and changes in myofi-
brillar proteins related to diabetes [14] might theoretically
diminish the magnitude of reverse remodeling and the
benefits on outcomes provided by CRT. These cardiac
abnormalities, together with other major systemic
changes induced by DM, may theoretically affect the ef-
ficacy of CRT.
The impact of diabetes on advanced HF in patients
undergoing CRT was first addressed in a small study by
Kies et al. [9]. After 6 months of CRT, response and
long-term survival did not differ for patients with or
without DM. Recently, the random controlled trial
CARE-HF [11] showed that diabetic and non-diabetic
patients undergoing CRT had a similar incidence of the
combined end-point of death and unplanned hospitalisa-
tions for cardiac reasons. Regardless of the diabetes ther-
apy and the presence of coronary artery disease, diabetes
did not influence the beneficial effect of CRT on any
endpoint. However, other research found diabetic pa-
tients with worse recovery of left ventricular ejection
fraction over time (P = 0.057) and distance in the 6-min
walking test (P = 0.018) than non-diabetic patients.
Insulin-treated diabetes is associated with poor func-
tional recovery and increased mortality in patients with
advanced HF after CRT. Moreover, we found higher total
mortality for patients with than without diabetes who
had advanced HF and were undergoing CRT, independ-
ent of baseline characteristics. The increased risk of
death for diabetic patients seems to be explained mainly
by patients with insulin-treated diabetes [13].
Study suggested that patients with HF and DM (in
particular insulin-treated DM) who undergo CRT seem
to have worse prognosis than non-diabetic patients[9,11]. This finding may be due to a high incidence of is-
chemic etiology of HF and a limited effect of CRT on re-
verse left ventricle (LV) volumetric remodeling in these
patients. The ischemic etiology of HF is an independent
predictor of poor echocardiographic response to CRT.
Patients with DM and HF have a relatively poor echocar-
diographic response to CRT [15], which may limit the
effect of CRT on reverse LV volumetric remodeling in
these patients. However, in 2 previously published CRT
series, left ventricular dimensional and functional
changes were similar for patients with and without DM
[9]. This finding seems controversial, because patients
with DM have a high incidence of coronary artery dis-
ease as an underlying etiology of HF. In several studies,
ischemic etiology was found a negative predictor of re-
verse LV volumetric remodeling [16-18], which may be
due to the progressive character of coronary artery dis-
ease and the presence of scar tissue not responsive to
pacing [19]. So, the effect of diabetes on myopathic
mechanisms and progression of cardiac dysfunction
might influence the response of HF patients to CRT.
Recent observations suggest that diabetes treated or
not with insulin has a different impact on mortality in
advanced HF even after CRT [11,20]. Insulin use rather
than diabetes may be the marker of adverse prognosis in
patients with systolic HF. Patients not receiving insulin
may at little or no increased risk of death. Insulin may
be a marker of more severe and/or longer duration of
diabetes and, therefore, risk of micro- and macrovascular
complications of diabetes. The CARE-HF data are con-
sistent with the association of insulin use or requirement
and worse outcome rather than diabetes diagnosis. Ap-
propriate RCTs are required to determine whether insu-
lin is a marker or mediator of worse outcome.
In non-diabetic people, CRT significantly improves
NYHA functional class and peak oxygen consumption
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Similar significant changes were observed in diabetic pa-
tients [12], which confirms the cardiac and systemic im-
provements of CRT in patients with more severe
abnormalities. Indeed CRT-induced improvements in
NYHA functional class, daily spontaneous physical activ-
ity (evaluated by automatic monitoring of Activity-log
Index from last-generation devices), and left ventricular
end-systo/diastolic diameters were comparable in dia-
betic and non-diabetic patients. The trend toward lower
baseline peak oxygen consumption and larger ventricu-
lar dimensions in diabetic versus non-diabetic patients
indirectly confirms the greater severity of illness in the
diabetic group. Left ventricular ejection fraction and
oxygen consumption at peak were significantly greater
in non-diabetic than diabetic patients with CRT, which
suggests better improvement of functional capacity after
CRT in non-diabetic patients.
Conclusions
This meta-analysis suggests that diabetic patients with
advanced HF undergoing CRT exhibit higher total mor-
tality than nondiabetic patients. The increased risk of
death of diabetic patients with HF seems to be mainly
explained by patients with insulin-treated diabetes. The
survival estimates for nondiabetic and noninsulin-
treated diabetic patients were similar, whereas that for
insulin-treated patients was substantially worse. Intri-
guingly, cardiac death accounted for most of the deaths
in patients without diabetes, but a relevant proportion of
the excess mortality of patients with diabetes seemed to
result from noncardiac causes. CRT had a beneficial ef-
fect on reverse remodeling in all patient groups (without
diabetes, with noninsulin-treated diabetes, with insulin-
treated diabetes), with a slight but not statistically sig-
nificant increased improvement in ejection fraction in
nondiabetic patients. However, diabetic patients had a
smaller increase in exercise tolerance over time. This
finding may reflect the presence of vascular and periph-
eral neurological disease and less-efficient muscular me-
tabolism in this population or more severe diastolic
impairment in diabetic patients, [12] Future research
could investigate possible “peripheral” versus “central”
factors that may explain why diabetic patients present less
functional improvement during follow-up. Although
insulin-treated diabetic patients shows poorer survival
than the other 2 patient groups, we cannot conclude that
insulin-treated diabetic patients do not benefit from CRT
because of the absence of a control group without CRT in
the studies. A recent analysis of data from the CARE-HF
trial, including a control group, showed that insulin-
treated diabetic patients had a markedly worse prognosis
than nondiabetic patients and that CRT was equally effect-
ive in both patient groups in reducing mortality.In our group of advanced HF patients, CRT significantly
improved functional capacity, promoted reversal of the
maladaptive remodeling process, and reduced the sympa-
thetic drive to the heart in both diabetic and non-diabetic
patients, over a long period of time. Consistently, morbidity
and mortality were comparable between diabetic and
non-diabetic CRT patients. Further evidence to support
or refute the negative prognostic role of diabetes in
CRT patients is now required.
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